Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

, ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

10:34
09/22/18
09/22
10:34
09/22/18
10:34

'Good time' to think about device markers, Barron's says

Medical technology stocks have reached their highest valuations in decades, but unlike some sectors, shares might stay aloft, Bill Alpert writes in this week's edition of Barron's. Hot performers among medical-device stocks this year include Boston Scientific (BSX) and Intuitive Surgical (ISRG), each up 50%, the report notes, adding that med tech trades at a premium given its double-digit sales growth and scarcity. Reference Link

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

  • 09

    Oct

BSX Boston Scientific
$37.76

-0.07 (-0.19%)

09/10/18
NEED
09/10/18
NO CHANGE
Target $43
NEED
Strong Buy
Boston Scientific price target raised to $43 from $39 at Needham
Needham analyst Mike Matson raised his price target on Boston Scientific to $43 and kept his Strong Buy rating. The analyst cites the company's latest $500M bid Augmenix, whose SpaceOAR reduces side effects associated with prostate radiotherapy. While the company expects "immaterial" earnings impact from the deal through 2019, Matson believes that it will strengthen its Urology & Pelvic Health business longer term, with added potential "revenue synergies given BSX's NxThera acquisition and legacy GreenLight XPS system".
09/05/18
ARGS
09/05/18
NO CHANGE
Target $41
ARGS
Buy
Boston Scientific price target raised to $41 from $36 at Argus
Argus analyst Jasper Hellweg raised his price target on Boston Scientific to $41 and kept his Buy rating, saying the company's outperformance over the past 3 months has been driven by its new product and acquisition news. Hellweg further cites the company's Q2 results showing organic sales growth up in all 3 of its sectors and across all regions. The analyst also notes that the stock price is trading in a bullish pattern of higher lows and highs going back to 2012 and believes that Boston Scientific is deserving of its premium valuation based on its growth outlook and profitability profile.
09/04/18
09/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Strong Buy from Market Perform at Raymond James with analyst Patrick Tyler Brown saying he believes investors are underappreciating UPS' long-term Domestic EBIT and 2021 free cash flow outlook, which could be greater than $8B. 2. Qualcomm (QCOM) upgraded to Outperform from Neutral at Macquarie with analyst Srini Pajjuri saying he believes risk/reward is attractive and sees multiple catalysts ahead including a final settlement with Huawei in the near future, increasing probability of an Apple (AAPL) settlement, and a 5G cycle that is not fully reflected in consensus estimates. 3. Albemarle (ALB) upgraded to Buy from Hold at SunTrust with analyst James Sheehan saying investors have driven down the price of the stock amid lithium oversupply concern on incorrect assumption that it is a commodity. 4. Univar (UNVR) upgraded to Buy from Hold at Berenberg with analyst Thomas Burlton saying the company is improving its conversion margin and EBITDA growth while its cash generation is also getting better. 5. Boston Scientific (BSX) upgraded to Buy from Hold at Jefferies with analyst Raj Denhoy citing a survey of 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/04/18
JEFF
09/04/18
UPGRADE
Target $42
JEFF
Buy
Jefferies upgrades Boston Scientific to Buy after TAVR doctor survey
Jefferies analyst Raj Denhoy upgraded Boston Scientific (BSX) to Buy from Hold and raised his price target for the shares to $42 from $34. He upgraded the shares after surveying 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market, Denhoy tells investors in a research note. He notes that by 2022, the U.S. TAVR market is expected to be $3.1B and the global market $6.5B. Boston Scientific's revenue growth can be sustained at 7% through at least 2022, Denhoy writes. That level of growth keeps Boston Scientific at the upper end of medtech growth and supports a positive view on the stock, the analyst adds.
ISRG Intuitive Surgical
$556.70

-4.43 (-0.79%)

09/13/18
PIPR
09/13/18
NO CHANGE
PIPR
Piper sees minimal impact to Medtech space from Hurricane Florence
Piper Jaffray analyst Matt O'Brien says he's heard investor concerns over the impact on Medtech companies with Hurricane Florence set to impact the Carolinas in the next 48 hours. While the analyst anticipates some delays, he believes the overall impact to the space will be minimal, ranging between 10-60 basis points of Q3 revenue for most companies in the region. On the supply-side, Teleflex (TFX), Baxter (BAX), Merit Medical (MMSI), and Intuitive Surgical (ISRG) have the most manufacturing and distribution exposure in North Carolina, South Carolina, Georgia and Virginia, O'Brien tells investors in a research note. However, the analyst adds that many of these locations could be unaffected depending on the storm's path. He believes any hurricane-related weakness in the Medtech shares is likely to be transient and "potentially provide more attractive entry points."
09/12/18
WELS
09/12/18
NO CHANGE
Target $635
WELS
Outperform
Intuitive Surgical price target raised to $635 from $575 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Intuitive Surgical to $635 from $575 on his 2020 EPS estimate, which represents a premium to the large cap medtech peers. The analyst notes that the company has filed a complaint against Auris Health, alleging that the company's Monarch endoscopy platform that received FDA 510k clearance on March 22 infringes on eight patents held by Intuitive. It further alleges that Monarch will compete directly with Intuitive's Flex platform that is awaiting FDA clearance for use in lung biopsies, Biegelsen adds. After his patent consultant reviewed the complaints, the analyst believes Intuitive's case may be weak, but is not likely to have an impact on the company given that the underlying markets are large and underserved with room for both competitors. He reiterates an Outperform rating on Intuitive shares.
07/20/18
STFL
07/20/18
NO CHANGE
Target $600
STFL
Buy
Intuitive Surgical price target raised to $600 from $515 at Stifel
Stifel analyst Rick Wise said Intuitive Surgical "emphatically checked every important box" with its Q2 report, noting that its procedures growth, systems shipments, and EPS all meaningfully topped expectations. Following the report, he raised his 2018-2020 sales and EPS projections and increased his price target on the stock to $600. Wise keeps a Buy rating on Intuitive shares.
07/20/18
MSCO
07/20/18
NO CHANGE
Target $575
MSCO
Overweight
Intuitive Surgical price target increased to $575 from $535 at Morgan Stanley
Morgan Stanley analyst David Lewis increased his price target on Intuitive Surgical to $575 from $535, stating that "inflection in the core is evident" given the better than expected procedure growth and system upside reported in Q2. With trends in procedures and systems strong, he is confident in growth sustainability and he is additionally confident that Intuitive will not only to maintain technological leadership but materially expand its addressable market with new introductions, Lewis tells investors. He maintains an Overweight rating on Intuitive shares.

TODAY'S FREE FLY STORIES

ISR

IsoRay

$0.50

0.0191 (3.98%)

17:25
10/19/18
10/19
17:25
10/19/18
17:25
Syndicate
Breaking Syndicate news story on IsoRay »

IsoRay files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHS

Neuberger Berman High Yield Strategies Fd

$10.55

-0.015 (-0.14%)

17:06
10/19/18
10/19
17:06
10/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Neuberger Berman High Yield Strategies Fd »

Saba Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOC

Biocept

$2.27

-0.04 (-1.73%)

17:04
10/19/18
10/19
17:04
10/19/18
17:04
Syndicate
Breaking Syndicate news story on Biocept »

Biocept files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$726.10

-4.09 (-0.56%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Hot Stocks
AutoZone founder Hyde will not stand for board re-election »

AutoZone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SACH

Sachem Capital

$4.33

0.02 (0.46%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Syndicate
Breaking Syndicate news story on Sachem Capital »

Sachem Capital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

16:53
10/19/18
10/19
16:53
10/19/18
16:53
Conference/Events
Mirati Therapeutics to hold a conference call »

Dr. Charles Baum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPNE

SeaSpine

$16.58

-0.54 (-3.15%)

16:47
10/19/18
10/19
16:47
10/19/18
16:47
Hot Stocks
Breaking Hot Stocks news story on SeaSpine »

First Light Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

16:46
10/19/18
10/19
16:46
10/19/18
16:46
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGLS

Tecnoglass

$9.72

(0.00%)

16:35
10/19/18
10/19
16:35
10/19/18
16:35
Syndicate
Breaking Syndicate news story on Tecnoglass »

Tecnoglass files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

16:30
10/19/18
10/19
16:30
10/19/18
16:30
Options
Preliminary option volume of 24.7M today »

Preliminary option volume…

OXM

Oxford Industries

$81.36

-1.68 (-2.02%)

16:28
10/19/18
10/19
16:28
10/19/18
16:28
Conference/Events
Oxford Industries management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HELE

Helen of Troy

$120.52

0.31 (0.26%)

16:26
10/19/18
10/19
16:26
10/19/18
16:26
Conference/Events
Helen of Troy management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CGA

China Green

$0.74

0.0584 (8.57%)

16:21
10/19/18
10/19
16:21
10/19/18
16:21
Hot Stocks
China Green receives NYSE notice regarding late Form 10-K filing »

China Green Agriculture…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Options
Closing CBOE SPX and VIX Index summary for October 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Conference/Events
Morgan Stanley energy analyst to hold an analyst/industry conference call »

Refining & Canadian…

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Hot Stocks
Bristol-Myers updates on use of Opdivo and Yervoy in first-line lung cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
10/19/18
10/19
16:17
10/19/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNGO

Bionano Genomics

$6.98

0.08 (1.16%)

16:17
10/19/18
10/19
16:17
10/19/18
16:17
Hot Stocks
Bionano Genomics and GrandOmics partner to offer genetic test for FSHD in China »

Bionano Genomics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEP

Holly Energy Partners

$30.73

-0.2 (-0.65%)

16:16
10/19/18
10/19
16:16
10/19/18
16:16
Hot Stocks
Holly Energy Partners raises quarterly distribution to 66.5c from 66c per unit »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SES

Synthesis Energy Systems

$1.70

-0.075 (-4.23%)

16:16
10/19/18
10/19
16:16
10/19/18
16:16
Hot Stocks
Synthesis Energy Systems receives non-compliance letter from Nasdaq »

Synthesis Energy Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
10/19/18
10/19
16:16
10/19/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.